Get your health and wellness news from Nepal
Provided by AGP
Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies
Phase 1 study builds on early signals of anti-tumor activity in patients with refractory T and B cell lymphomas
Ipsoprubart, a first-in-class SIRP-targeting therapy, expands into T cell malignancies alongside ongoing pivotal study in secondary hemophagocytic lymphohistiocytosis (sHLH)
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced dosing of the first patient in a Phase 1 study of ipsoprubart (ELA026) in patients with T cell malignancies. Ipsoprubart, a first-in-class monoclonal antibody targeting signal regulatory proteins (SIRP) on immune cells, is designed to selectively deplete pathological T cells and myeloid cells, with the potential to inhibit tumor growth and survival through both direct tumor cell elimination and tumor microenvironment modulation.
Initial evidence of anti-tumor activity in lymphoma, including T cell malignancies, was observed in a Phase 1b study of ipsoprubart in secondary hemophagocytic lymphohistiocytosis (sHLH), in patients whose disease was triggered by the underlying lymphoma. These findings supported advancement into a dedicated study in T cell malignancies, extending the clinical program for ipsoprubart beyond the ongoing pivotal study in sHLH. The Phase 1 study in T cell malignancies will evaluate safety and efficacy in patients treated with ipsoprubart monotherapy. T cell malignancies are a group of rare, aggressive lymphomas and leukemias arising from mature or immature T lymphocytes. More than 13,000 patients in the US are diagnosed annually with T cell malignancies and have limited effective treatment options that provide durable disease control.
“Our team has pioneered SIRP targeting as a therapeutic approach to selectively deplete pathological immune cells,” said Kathy Dong, PharmD, MBA, President and CEO of Electra Therapeutics. “We are excited to follow the science and expand into T cell malignancies, where new treatment approaches are needed for patients and ipsoprubart has shown promising potential.”
The open-label Phase 1 study will enroll adults with relapsed or refractory T cell malignancies. Patients may receive up to six cycles (24 weeks) of treatment with ipsoprubart. The study consists of two parts: Part 1 will enroll up to 24 patients to identify up to two dosing regimens with acceptable safety profiles; Part 2 will further evaluate these regimens in expansion cohorts. The primary endpoint is safety, including drug-related toxicities and treatment-emergent adverse events. Secondary endpoints include overall response rate, duration of response, and disease control rate. Additional details are available on clinicaltrials.gov (NCT07465835).
“The initiation of this study reflects strong interest from clinical investigators who were highly encouraged by the anti-tumor effect observed within weeks of treatment with ipsoprubart in the Phase 1b study in sHLH,” said Kim-Hien Dao, DO, PhD, Chief Medical Officer of Electra Therapeutics. “Patients with relapsed or refractory T cell malignancies have limited treatment options and poor outcomes. The promising activity observed in heavily treated patients, including responses to ipsoprubart monotherapy, supports our further evaluation in this setting.”
Clinical Data for Ipsoprubart (ELA026) in Lymphomas, Including T Cell Malignancies
Anti-tumor activity of ipsoprubart in lymphoma was observed in a Phase 1b study in sHLH, including in patients whose disease was triggered by T cell malignancies. Among eight patients with lymphoma-associated sHLH, six of whom had T cell malignancies as the underlying trigger, the objective tumor response rate was 100% (8/8), with a complete response rate of 88% (7/8), including one durable complete response achieved with ipsoprubart monotherapy in a T cell lymphoma patient refractory to more than five lines of prior therapy. These findings were first reported in a presentation titled “ELA026, a Monoclonal Antibody Targeting SIRP-expressing Myeloid Cells and T Lymphocytes, Demonstrates Broad Anti-tumor Activity in Patients with Lymphoma” at the International Conference on Malignant Lymphoma in 2025.
About Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer. The company’s lead product candidate, ipsoprubart (ELA026), is a first-in-class monoclonal antibody targeting signal regulatory proteins (SIRP) on immune cells to selectively deplete pathological T lymphocytes and myeloid cells. Ipsoprubart is in a pivotal clinical trial for secondary hemophagocytic lymphohistiocytosis (sHLH) and is being evaluated in another clinical trial for T cell malignancies. Electra is also advancing ELA822, a SIRP-targeted antibody designed to selectively deplete activated T lymphocytes, with potential applications across immunology and inflammation (I&I). For more information, please visit electra-therapeutics.com and follow us on LinkedIn.
Investor Contact: Chris Clark Electra Therapeutics cclark@electra-therapeutics.com Media Contact: Kathryn Morris The Yates Network 914-204-6412 kathryn@theyatesnetwork.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
